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LymphocyteThe anti-apoptotic protein Bcl-2 is a versatile regulator of cell survival. Its interactionswith its own pro-apoptotic
family members are widely recognized for their role in promoting the survival of cancer cells. These interactions
are thus being targeted for cancer treatment. Less widely recognized is the interaction of Bcl-2 with the inositol
1,4,5-trisphosphate receptor (InsP3R), an InsP3-gated Ca2+ channel located on the endoplasmic reticulum. The
nature of this interaction, the mechanism by which it controls Ca2+ release from the ER, its role in T-cell devel-
opment and survival, and the possibility of targeting it as a novel cancer treatment strategy are summarized in
this review. This article is part of a Special Issue entitled: Calcium signaling in health and disease. Guest Editors:
Geert Bultynck, Jacques Haiech, Claus W. Heizmann, Joachim Krebs, and Marc Moreau.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
It has been almost thirty years since Bcl-2 was discovered [1,2]
and found to be a positive regulator of cell survival [3]; twenty years
since the ﬁrst indication that Bcl-2 regulates intracellular Ca2+ dynam-
ics [4,5], and ten years since an interaction of Bcl-2 and its close relative
Bcl-xl with the inositol 1,4,5-trisphosphate receptor (InsP3R) was dis-
covered [6,7]. An inhibitor of the Bcl-2–InsP3R interaction has recently
been developed and shown to induce the death of primary human
chronic lymphocytic leukemia (CLL) cells [8,9], raising the possibility
that targeting this interaction may become a novel treatment strategy
for Bcl-2-positive malignancies. This review will discuss our under-
standing of how the Bcl-2–InsP3R interaction promotes cell survival,
with the evidence that Bcl-2-positive cancer cells exploit this, Bcl-2 homology; CaN, calcine-
osphate receptor-derived pep-
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berg), arl18@case.edumechanism to avoid cell death, and the efforts to therapeutically target
the Bcl-2–InsP3R interaction. Readers are referred to a number of excel-
lent reviews for expanded information about InsP3Rs and Ca2+ signal-
ing [10,11] and the Bcl-2 protein family [12,13].
2. Bcl-2 family members and functions
Bcl-2 is a 26 kDa integralmembrane protein that resides on theouter
mitochondrial membrane and endoplasmic reticulum (ER) membrane.
It is anchored on these membranes by a C-terminal hydrophobic tail
and is mainly cytoplasmic in location. Bcl-2 excited great interest
when it was discovered to promote cell survival by inhibiting apoptosis
[3]. One after another, Bcl-2 relatives were identiﬁed, elevating Bcl-2 to
pater familias stature. Proteins in the Bcl-2 family share sequencemotifs
referred to as Bcl-2 Homology Domains (BH domains), of which four are
recognized (Fig. 1). From a functional standpoint, members generally
fall into two opposing groups: anti-apoptotic proteins and pro-
apoptotic proteins. Anti-apoptotic members such as Bcl-2 typically
have four BH domains (BH1–4). Pro-apoptotic members fall into two
subgroups: those with three BH domains (BH1–3), such as Bax and
Bak, and thosewith only a BH3 domain, the ‘BH3-only proteins’, includ-
ing for example Bim, Bad, and PUMA. These distinctions are useful from
an operational standpoint, but are undergoing signiﬁcant revision and
clariﬁcation as an increasing number of proteins are found to have
BH3-like domains but not all are Bcl-2 family members [14]. Moreover,
only anti-apoptotic members were originally considered to have BH4
Fig. 1. Bcl-2–InsP3R interaction and its peptide inhibitor. (A) The location of Bcl-2 homology (BH) domains is shown, together with proteins known to interact with the BH4 domain and
with a hydrophobic cleft composed of BH 1–3 domains. (B) The diagram illustrates the interaction of the BH4 domain of Bcl-2 with a region within the regulatory and coupling domain of
the InsP3R. IDP is a synthetic peptide corresponding to a 20 amino acid sequence within the Bcl-2 binding site on the InsP3R. IDPDD/AA is a modiﬁcation of IDP that eliminates a predicted
cleavage site and increases the peptide's activity when introduced into cells by fusion with the cell penetrating peptide of HIV TAT.
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become recognized in certain pro-apoptotic family members [14].
One of themost remarkable features of Bcl-2 is its lack of an obvious
inherent function, such as kinase, phosphatase or enzymatic activity.
Bcl-2 and its anti-apoptotic relatives nevertheless exert widespread in-
ﬂuence over many cell functions, ultimately inﬂuencing cell survival.
The main modus operandi involves engagement in diverse interactions.
These include homomeric and heteromeric oligomerization involving
both Bcl-2 family members and non-family proteins. A major activity
of Bcl-2 involves interaction with its pro-apoptotic family members, in-
cluding Bax, Bak and the BH3-only members. By binding pro-apoptotic
family members, Bcl-2 prevents these proteins from oligomerizing and
forming pores in the outer mitochondrial membrane, thus releasing cy-
tochrome c and activating a cascade of caspase activation, ultimately
leading to apoptosis. Bcl-2's site of interaction with pro-apoptotic pro-
teins is located in a hydrophobic cleft composed of BH1–3 domains
(Fig. 1). This cleft is occupied by small molecule BH3-mimetics such as
ABT-737 that displace pro-apoptotic proteins from Bcl-2 and thus trig-
ger apoptosis [15,16]. For an in-depth explanation of howBcl-2 interacts
with its pro-apoptotic relatives, thereby preserving outermitochondrial
membrane integrity, the reader is referred to publications by Llambi
et al. [17] and Shamas-Din et al. [13].
Bcl-2 family proteins also regulate cell survival through their locali-
zation to the ER [18,19].Moreover, Bcl-2 interactswith a number of pro-
teins in addition to Bcl-2 protein family members, indicating that Bcl-2
has functional signiﬁcance beyond its direct control of pro-apoptotic
relatives (Fig. 1). These interactions are mediated through the BH4
domain and include binding of the BH4 domain to InsP3Rs, the serine/
threonine protein kinase Raf-1 [20] and the serine/threonine
protein phosphatase calcineurin (CaN) [21]. Raf-1 phosphorylates and
thereby inhibits the pro-apoptotic protein Bad [20]. The interaction of
the Bcl-2 BH4 domain with CaN and the InsP3R regulates intracellular
Ca2+ dynamics and cell survival, as addressed in this review.Fig. 2. ER–mitochondria Ca2+ transfer. InsP3R-mediated transfer of Ca2+ from the ER
lumen into the mitochondrial matrix is of vital importance since Ca2+ activates multiple
steps in the citric acid cycle, promoting ATP production.3. Regulation of cell survival and cell death by InsP3R-mediated
Ca2+ elevation
InsP3Rs are InsP3-gated Ca2+ channels locatedmainly on the ER [10,
11] (Fig. 2). Their central function is to release Ca2+ ions from the ER
lumen, where Ca2+ is stored at high concentration. Ca2+ release in-
duces highly regulated and systematic elevations of cytoplasmic Ca2+
concentration. InsP3R-mediated Ca2+ elevation regulates the activity
of many fundamental cellular processes including fertilization, cell
cycle entry, cell division,metabolism, and transcription [10,22]. Ca2+ in-
formation is encoded in the frequency and amplitude of Ca2+ oscilla-
tions and decoded by Ca2+-sensitive kinases and phosphatases, inturn regulating the activity of target proteins as diverse as transcription
factors, endonucleases, proteases and metabolic enzymes [23,24].
One of the most important functions of InsP3R-mediated Ca2+ sig-
naling is the promotion of cell survival by supporting mitochondrial
Ca2+ uptake and mitochondrial metabolism. The close proximity of
ER-localized InsP3Rs to mitochondria facilitates Ca2+ transfer from the
ER lumen into the mitochondria [25,26] (Fig. 2). This calcium transfer
promotes mitochondrial ATP production by catalyzing the conversion
of pyruvate to acetyl-CoA and by activatingmultiple Ca2+-sensitive en-
zymes in the citric acid cycle [27,28]. Insufﬁcient ER-mitochondrial
Ca2+ transfer results in autophagy, a survival mechanism through
which cells digest intracellular components in order to produce ATP
[29], but which may lead to cell death if prolonged (Fig. 3). Conversely,
excessive transfer of Ca2+ to mitochondria induces Ca2+ overload,
resulting in loss ofmitochondrialmembrane potential, cytochrome c re-
lease and apoptosis [30,31] (Fig. 3). Therefore, although Ca2+ elevation
plays a critical role in promoting cell survival, it is also a known inducer
of cell death [32,33] and for this reason InsP3R-mediated Ca2+ release
Fig. 3.Control over InsP3R-mediated Ca2+ release and its importance. The consequences of
insufﬁcient or excessive Ca2+ transfer from ER to mitochondria illustrate why cells have
developed a number of mechanisms, including interaction with Bcl-2, to control InsP3R
channel opening and Ca2+ release. Fig. 4. Dynamic ﬂuctuations in Bcl-2 levels throughout T-cell development and adult life.
The complexity of the immune system is dependent, in part, upon variation in Bcl-2 ex-
pression. Bcl-2 levels are sufﬁcient to repress apoptosis during the earliest stages of lym-
phocyte precursor development in the fetal liver and bone marrow, and during the
journey from these distant organs to the thymus gland. Bcl-2 levels then decline upon
entry into the thymic cortex, allowing for apoptotic death of most young thymocytes
through negative selection, a process that deletes thymocytes that strongly react with
self-antigens. Thymocytes that onlyweakly reactwith self-antigens are allowed to survive
in a process of positive selection and enter the thymicmedulla where Bcl-2 levels become
elevated in preparation for survival of mature lymphocytes in peripheral organs including
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through a number of different pathways in addition to mitochondrial
Ca2+ overload. These include activation of Ca2+-sensitive proteases
and endonucleases, activation of the pro-apoptotic Bcl-2 familymember
Bad, and inducing expression of pro-apoptotic Bcl-2 familymember Bim
[33].blood and lymph nodes. Bcl-2 levels further increase when a mature lymphocyte is acti-
vated to proliferate in response to antigenic stimulation, but then decline later as the im-
mune response declines, an apoptotic process referred to as activation-induced cell death.4. Bcl-2 regulation of InsP3R-mediated Ca
2+ elevation in T-cells
Our work has focused on the role of Bcl-2 in regulating InsP3R-
mediated Ca2+ signals in T-cells. Bcl-2 is of critical importance in T-cell
development and survival. The developing T-cell passes through succes-
sive maturational stages within the thymus [34] and Bcl-2 levels vary
considerably throughout these different developmental stages [4,35,
36] (Fig. 4). The earliest precursors from the bone marrow or
fetal liver do not express either the TCR or the CD4 and CD8 antigens
(i.e., ‘double negative stage’), but do express Bcl-2: this provides an ele-
ment of protection from apoptosis en route to the thymus gland. In the
cortex of the thymus these immature T-cells express the TCR and
both CD4 and CD8 antigens (i.e., ‘double positive stage’). Bcl-2
levels are down-regulated at this stage, increasing their sensitivity to
Ca2+-induced apoptosis [4]. This facilitates a stringent test of whether
or not the T-cells respond to self-antigens, with strong responders un-
dergoing apoptosis (‘negative selection’) andweak responders avoiding
apoptosis (‘positive selection’) [37,38]. During negative selection,
apoptosis is induced by Ca2+-dependent up-regulation of the pro-
apoptotic Bcl-2 family member Bim [39]. Surviving cells advance to
the ‘single positive stage’ (CD4+/CD8−, CD4−/CD8+), where Bcl-2
levels are increased, and enter the circulation to mount immune re-
sponses to foreign antigens as mature T cells. Bcl-2 levels are further el-
evated when a T-cell responds to antigenic stimulation and proliferates,
but then decline as the immune response wanes and the T-cell dies, a
process referred to as activation-induced cell death.
The role of Bcl-2 in T-cell development was elegantly demonstrated
by Bcl-2 knockout and over-expression strategies. The Bcl-2 knockout
mouse, developed in the laboratory of Stanley Korsmeyer, demonstrat-
ed extensive lymphoid apoptosis [40]. Conversely, enforced expression
of Bcl-2 in transgenic mice inhibited negative selection, causing exces-
sive accumulation of thymocytes [41,42]. Transgenic Bcl-2 inhibits neg-
ative selection by a mechanism independent of its ability to antagonizeBax, suggesting a role for Bcl-2-mediated regulation of Ca2+ in this pro-
cess [43,44].
The InsP3R-mediated Ca2+ signals induced by T-cell receptor (TCR)
activation are of critical physiological importance in the developing im-
mune system [39,45,46]. Positive versus negative selection decisions in
the thymus may be encoded by distinct Bcl-2-regulated Ca2+ signaling
patterns [47]. T-cell activation by antigen binding to the TCR triggers a
signaling cascade that activates phospholipase C-γ, generating InsP3.
InsP3 binds to the InsP3R, inducing channel opening and Ca2+ release
from the ER, thus stimulating T-cell proliferation [45,48–50]. Depending
on the strength of TCR activation, a variety of Ca2+ response patterns
are generated, including transient Ca2+ elevation, sustained Ca2+ eleva-
tion, or Ca2+ oscillations [51,52]. TCR activation by physiologically-
relevant antigenic peptides in immature thymocytes produces a similar
effect: negatively-selecting antigenic peptides induce a strong Ca2+
ﬂux, whereas positively-selecting peptides induce a smaller Ca2+
ﬂux [53]. Additionally, earlier studies in thymocytes demonstrated
that cytoplasmic Ca2+ elevation following strong TCR activation by a
high concentration of anti-CD3 antibody in vitro induces apoptosis,
whereas cytoplasmic Ca2+ elevation induced by weak TCR activation
using lower concentrations of anti-CD3 antibody does not trigger
apoptosis [54].5. Effect of Bcl-2 on Ca2+ signaling
We investigated the effect of Bcl-2 on Ca2+ signaling patterns in the
murine thymocyte line, WEHI7.2. These cells correspond to the double
positive stage of thymocyte development and thus have very low levels
of Bcl-2. We ﬁnd that strong TCR activation by a high concentration of
anti-CD3 antibody induces a large transient Ca2+ elevation, whereas
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duces sustained Ca2+ oscillations [47]. These Ca2+ signaling patterns
differ in two ways: high anti-CD3 induces a much more prolonged
Ca2+ elevation than low anti-CD3 (N4 min versus b1 min); and high
anti-CD3 triggers a higher peak Ca2+ amplitude than low anti-CD3
[47]. High amplitude Ca2+ elevation, particularly if continuous and
sustained, triggers cell death [32,33]. Thus, consistent with the earlier
ﬁndings of other investigators, the critical determinant of whether or
not TCR stimulation induces apoptosis appears to lie in both the dura-
tion and amplitude of the Ca2+ elevation.
We ﬁnd that Bcl-2 selectively inhibits the pro-apoptotic Ca2+ eleva-
tion induced by strong TCR activation while enhancing the pro-survival
Ca2+ oscillations induced by weak TCR activation [47]. The positive ef-
fect of Bcl-2 on Ca2+ oscillations and its pro-survival effects are consis-
tent with a number of other ﬁndings. For example, Ca2+ oscillations
regulate thymocytemotility during positive selection, therebymodulat-
ing interactions with stromal cells [55]. Ca2+ oscillations also lead to a
sustained activation of CaN [38], which dephosphorylates and thereby
activates NFAT, increasing expression of the gene encoding the cytokine
interleukin-2 [48,51,56].
Moreover, although this review emphasizes Bcl-2–InsP3R interac-
tion in the context of regulating cell death, the regulatory role of this in-
teraction extends far beyond cell death to include many processes in
which Ca2+ signaling plays important roles. As an example, elegant
experiments by Gillet et al. [57] indicate that the zebraﬁsh homolog of
Bcl-2, Nrz, interacts with InsP3Rs and controls cytoskeletal dynamics
via the regulation of Ca2+ trafﬁcking. Cytoskeletal dynamics are impor-
tant in cancer cell migration and metastasis and Bcl-2, by regulating
Ca2+, plays an important role in tumor metastasis and increased
tumor vascularity [58].
How Bcl-2 regulates InsP3R-mediated Ca2+ release is a major focus
in our laboratory. We discovered that Bcl-2 interacts with the InsP3R
[6] and that this interaction involves binding of the BH4 domain of
Bcl-2 to a region located within the regulatory and coupling domain of
the InsP3R [59,60] (Fig. 1).We synthesized a 20 amino acid peptide cor-
responding to theBcl-2 interaction site on the InsP3R and found that this
peptide, whichwe refer to as InsP3R-Derived Peptide (IDP), functions as
a decoy peptide that binds to Bcl-2 and inhibits Bcl-2–InsP3R interac-
tion. This peptide, as we found out, reverses the inhibitory effect of
Bcl-2 on InsP3R-mediated Ca2+ elevation in T-cells treated with high
concentrations of anti-CD3 antibody [59,60]. This peptide has proven
to be a valuable tool in studies of Bcl-2–InsP3R interaction.
Other anti-apoptotic Bcl-2 family members, including Bcl-xl and
Mcl-1, also interact with InsP3Rs and regulate InsP3R-mediated Ca2+ re-
lease [50,61]. Although these anti-apoptotic family members, and Bcl-2,
decrease ER luminal Ca2+ concentration, this has not been observed in
our studies [6,47,62]. A recent report also indicates that Bcl-2 may not
interact with InsP3Rs in all circumstances or cell types [63], raising the
important question of what actually regulates the Bcl-2–InsP3R interac-
tion in different types of cells.
Bcl-2 may also regulate ER Ca2+ release through other mechanisms
besides its interaction with the InsP3R. One proposed mechanism in-
volves Bcl-2 interaction with Sarcoplasmic/Endoplasmic Reticulum-
associated Ca2+-ATPase (SERCA). These proteins pump Ca2+ ions
from the cytoplasm into the ER lumen, maintaining large ER luminal
Ca2+ stores. This steep Ca2+ concentration gradient from ER lumen to
cytoplasm facilitates Ca2+ efﬂux from the ER lumen via InsP3R
channel opening, leading to cytoplasmic Ca2+ elevation. Bcl-2's interac-
tion with SERCA attenuates ER Ca2+ ﬁlling, indirectly diminishing
InsP3R-mediated Ca2+ release and Ca2+-mediated apoptosis [64,65].
Recent ﬁndings indicate that HSP70 regulates the Bcl-2–SERCA
interaction, maintaining SERCA in an active state that may be essential
for apoptosis regulation [66]. Accordingly, an earlier report of the Bcl-
2–SERCA interaction ﬁnds that Bcl-2 increases the ER Ca2+ pool, pro-
moting the high luminal Ca2+ concentration required for normal cell
function [67].6. How Bcl-2–InsP3R interaction regulates InsP3-mediated
Ca2+ release
The preceding ﬁndings illustrate the importance of InsP3R-mediated
Ca2+ signals in T-cells, and the role of Bcl-2 in regulating these signals.
However, it has not been determined how Bcl-2 regulates InsP3R-
mediated Ca2+ elevation through its interaction with the InsP3R.
Oakes et al. [68] show that Bcl-2 regulates InsP3R phosphorylation at
serine 1755 within the regulatory and coupling domain of the InsP3R
inmurine embryonic ﬁbroblasts. Protein kinase A (PKA) phosphorylates
serine 1755 and serine 1589 of the InsP3R, increasing InsP3-mediated
channel opening and Ca2+ release [64,69]. We previously reported
that Bcl-2 decreases InsP3R phosphorylation, although a speciﬁc phos-
phorylation site was not identiﬁed [6]. In recent work, we ﬁnd that
Bcl-2 inhibits InsP3R phosphorylation at serine 1755, correlating with
its inhibition of anti-CD3-induced Ca2+ elevation.
The mechanism underlying Bcl-2 regulation of InsP3R phosphoryla-
tion following TCR activation is under investigation in our laboratory.
PKA-mediated protein phosphorylation is typically regulated by PP1α
[70]. Tang et al. [71] discovered a direct association between PP1α and
InsP3R-1 and established that the association with PP1α reverses PKA-
mediated InsP3R-1 phosphorylation. Similarly, others have shown that
AKAP9, a multifunctional PKA anchoring protein, docks both PKA and
PP1α to InsP3R-1 [72]. Moreover, an InsP3R–PP1α complex has been
implicated in Bcl-2-mediated suppression of ER Ca2+ release in breast
cancer cells [70]. Bcl-2 also binds CaN [21] and increases the association
of CaN with InsP3Rs [72,73]; this has a neuroprotective effect in
primary neuronal cells [73]. Knowledge that Bcl-2 binds CaN, together
with evidence that PP1α reverses PKA-mediated InsP3R-1 phosphoryla-
tion, stimulated us to hypothesize a role for DARPP-32 (dopamine- and
c-AMP-regulated phosphoprotein of 32 kDa) in the regulation of
InsP3R-mediated Ca2+ elevation by Bcl-2.
DARPP-32 is a PKA-activated and CaN-deactivated PP1α inhibitor
studied extensively in the brain [74]. In experiments with medium
spiny neurons from DARPP-32 knockout mice, DARPP-32 was shown
to regulate dopamine-induced Ca2+ oscillations [75]. However, very lit-
tle is known about the role of DARPP-32 in peripheral tissues, including
lymphocytes, although DARPP-32 has been shown to increase the phos-
phorylation and activity of various ion channels [76]. We recently
found that Bcl-2 prevents exaggerated InsP3R-mediated Ca2+ elevation
in T-cells by decreasing InsP3R phosphorylation through a feedback
mechanism involving DARPP32 and CaN [77].
Although these recent ﬁndings establish a role for Bcl-2 in regulating
InsP3R phosphorylation, other potential mechanisms by which Bcl-2
and/or other anti-apoptotic members of the Bcl-2 family regulate
InsP3R-mediated Ca2+ signaling should be considered also. For exam-
ple, one report suggested that the Bcl-2 homologue Bcl-xl, affects
Ca2+ homeostasis by altering InsP3R levels [78]. More recent evidence
indicates that the Bcl-2 protein family member Bok binds to InsP3Rs
and protects them from proteolytic cleavage, although not governing
the ability of InsP3Rs to release Ca2+ [63]. Also, the possibility that cer-
tain Bcl-2 familymembersmay regulate InsP3 binding afﬁnity should be
considered [79].
7. Exploitation of the Bcl-2–InsP3R interaction by cancer cells and
targeting the Bcl-2–InsP3R interaction for cancer treatment
Anti-apoptotic Bcl-2 family members such as Bcl-2, Bcl-xl andMcl-1
play major roles in tumorigenesis by prolonging cancer cell survival
(reviewed in [80]). Anti-apoptotic Bcl-2 family members also regulate
the migration and invasion of colorectal cancer cells [81]. In general,
Bcl-2 is prominently expressed in leukemia and lymphoma cells,
whereas Mcl-1 is highly expressed in solid tumors in addition to lym-
phoid malignancies [82]. Moreover, ion channels such as the InsP3R
play extensive roles in regulating cell proliferation and cell death, and
are thus emerging as promising targets for cancer treatment [83].
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ﬂuxes to promote cell proliferation and avoid cell death [58,84]. This re-
modeling has important therapeutic implications.
Our work indicates that Bcl-2 promotes cancer cell survival by
interacting with InsP3Rs to prevent pro-apoptotic Ca2+ elevation
(Fig. 1), in addition to its known role in binding and inhibiting pro-
apoptotic family members. Small molecules that bind to the hydropho-
bic cleft formed by the BH1–3 domains of Bcl-2 displace pro-apoptotic
proteins from Bcl-2 and thus trigger apoptosis [15,16]. Thesemolecules,
including the Bcl-2 selective and platelet-sparing ABT-199, are already
in clinical trials for cancers as diverse as lymphoid malignancies, mye-
loid malignancies and breast cancer [15,16,85]. However, cancer cells
become resistant to virtually any single therapeutic approach. There-
fore, it is essential to target cancer cells from multiple angles if one
hopes to achieve a cure. For this reason, efforts are underway to target
the Bcl-2–InsP3R interaction. As summarized above, we have developed
a synthetic peptide corresponding to the InsP3R binding site for Bcl-2
[59,60] (Fig. 1). This InsP3R-Derived Peptide (IDP) inhibits the Bcl-2–
InsP3R interaction by binding to the BH4 domain of Bcl-2, destabilizing
Bcl-2's alpha-helical structure [59,60,86]. By inhibiting the Bcl-2–
InsP3R interaction, IDP and its protease resistant analog IDPDD/AA de-
crease Bcl-2's control over InsP3R-mediated Ca2+ elevation.
Bcl-2 elevation is a hallmark of chronic lymphocytic leukemia (CLL),
the most common form of leukemia in theWestern world. Initially, CLL
runs an indolent clinical course, providing a unique opportunity to in-
vestigate primary CLL cells before they are subjected to chemotherapy.
We ﬁnd that IDPDD/AA-mediated inhibition of Bcl-2–InsP3R interaction
induces marked Ca2+ elevation and Ca2+-mediated apoptosis in
primary human CLL cells, with minimal if any effect on the viability of
normal human lymphocytes [9]. IDPDD/AA also induces apoptosis in
Bcl-2-positive cell lines representing the B-cell malignancies, including
diffuse large cell lymphoma [87]. Also, in a preliminary study in CLL
cells, IDPDD/AA and the BH3-mimetic ABT-737 displayed synergistic cy-
totoxicity [8]. If conﬁrmed by additional in vivo testing, these ﬁndings
will underscore the value of simultaneously targeting Bcl-2's interaction
with both InsP3Rs and pro-apoptotic family members for cancer
treatment.
The usefulness of targeting the Bcl-2–InsP3R interaction may be de-
pendent upon a number of factors. One factor is the InsP3R isoform
expressed in different types of malignant cells. There are three InsP3R
isoforms, which vary in both tissue distribution and sensitivity to
Ca2+ and InsP3 regulation [88]. A recent study discovered that the sen-
sitivity of lymphoma cells to IDPDD/AA-induced apoptosis correlated
with InsP3R-2 isoform rather than InsP3R-1 or InsP3R-3 [87], which sug-
gests the InsP3R isoform expression in themalignancy being treatedwill
need to be considered in order to yield optimal therapeutic success. An-
other factor is the level of Bcl-2 in different types of cancer and the reli-
ance of various cancers on Bcl-2 for their survival [82]. Bcl-2 is typically
expressed in lymphoid malignancies, whereas other anti-apoptotic Bcl-
2 family members, such asMcl-1, predominate in non-lymphoid malig-
nancies. Individual anti-apoptotic family members may also differ in
their interaction with InsP3Rs [89]. Also, recent evidence indicates that
the BH4 domain of Bcl-xL binds to a different region on the InsP3R
than Bcl-2 [86]. Therefore, IDPDD/AA is more likely to be effective in kill-
ing malignant cells where Bcl-2 levels predominate over Bcl-xL levels.
8. Summary and future directions
This review has emphasized the role of the Bcl-2 protein in regulat-
ing InsP3R-mediated Ca2+ elevation, which both mediates normal cell
function and can induce cell death. Moreover, the review has focused
primarily on this function of Bcl-2 in the contexts of lymphocyte func-
tion and lymphoid malignancy. This focus should not be interpreted
as an indication, or even a suggestion, that Bcl-2 is the only familymem-
ber that regulates InsP3R-mediated Ca2+ release, as indeed a number of
Bcl-2 familymembers, including both anti-apoptotic and pro-apoptotic,are known to regulate Ca2+ release from the ER. Similarly, themain em-
phasis on lymphoid malignancies should not suggest that these are the
only malignancies in which Bcl-2 family members and Ca2+ regulation
are important. The reader is referred to an extensive review by Roderick
and Cook [84] of the many ways that Ca2+ signaling toolkit is
remodeled by cancer cells to promote their proliferation and survival.
In addition, the role of Ca2+ signaling in tumor cell migration and me-
tastasis, mentioned earlier in this review, has been thoughtfully
reviewed [58].
In sum, the discovery that Bcl-2 and its family members interact
with InsP3Rs and regulate InsP3-induced Ca2+ signals has brought
widespread attention to Ca2+ signaling and its exploitation by cancer
cells. Yet, this area of research deservesmore recognition among cancer
investigators than it seems to garner. This is likely due to the complexity
of Ca2+ signaling and the specialized nature of techniques employed to
study Ca2+ and Ca2+ signaling. With this oversight comes a loss of op-
portunity to target Ca2+ signaling pathways for cancer treatment. The
presently narrow emphasis of the cancer research ﬁeld on genomics is
sure to wane as the rate of progress plateaus and the interest turns
back to biology andphysiology, since itmay prove difﬁcult to correct de-
fective genes and a better investment of time and resources to develop
therapies based on the output of defective genes. We already witness
this trendwith the skyrocketing interest in autophagy and metabolism,
processes involving InsP3Rs and Ca2+ signaling.
For the immediate future, in-depth analysis of the differences be-
tween Bcl-2 family members in terms of their sites of interaction with
InsP3Rs and their differential effects on Ca2+ signaling is likely to gener-
ate new ideas and understanding, and to better elucidate the various
roles of Ca2+ in cancer. In addition, the next steps need tomove beyond
the present emphasis on Ca2+ in processes such as apoptosis and au-
tophagy, to expand our knowledge of the role of Ca2+ in metastasis,
which remains the major obstacle in our quest for cancer cure.Acknowledgements
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